We observed that β-escin targets HER2 and HER3, as well as the steric effects of p95HER2 and subsequently downregulates Akt in both trastuzumab-sensitive and -resistant HER2-positive breast cancer cells. This evidence concerns the gene ERBB2 and breast cancer.